BGB-10188

Tier C — Watch / trade

BGB-10188

BeiGene, Ltd.

Originator

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：PI3Kδ

Indications (approved)：Marginal zone B-cell lymphoma, Non-small cell lung cancer, Melanoma, Follicular lymphoma, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma, Solid tumour, Mantle cell lymphoma

Regional status

China

Phase II

2020-05-25

Japan

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of BGB-10188?

Approved indications include: Marginal zone B-cell lymphoma, Non-small cell lung cancer, Melanoma, Follicular lymphoma, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma, Solid tumour, Mantle cell lymphoma.

When does the BGB-10188 patent expire?

No public expiry year is available for BGB-10188 yet; this page updates once verified.

How do I get a quote for BGB-10188 intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-07